Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01848665
Other study ID # EEL 073.3
Secondary ID
Status Completed
Phase Phase 4
First received May 3, 2013
Last updated January 25, 2018
Start date May 2013
Est. completion date December 2016

Study information

Verified date January 2018
Source Brock University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Increased core temperature (hyperthermia) has been associated with impaired neuromuscular performance; however, the mechanisms associated with these performance decrements and their potential synergies remain unclear. While the majority of research suggests that the observed fatigue is related to the central nervous system, the influence of changes in cerebral blood flow (CBF) and associated changes in cerebral alkalosis (estimated by end-tidal partial pressure of carbon dioxide; PETCO2) remains unexamined. In response to hyperthermia, humans hyperventilate as means of heat dissipation, resulting in a hypocapnia (reduced PETCO2) mediated decrease in CBF and consequently, cerebral alkalosis (increased cerebral pH). Previous research suggests that hyperventilation induces changes in neural excitability and synaptic transmission; however, it remains unclear if these changes are related to hypocapnia mediated decrease in CBF or decreased PETCO2 or both.

The purpose of the proposed research program is to examine the influence of changes in CBF and cerebral alkalosis on neuromuscular function during passive heat stress. The research project will consist of 3 separate experimental trials: (a) poikilocapnic hyperthermia (increased core temperature; decrease CBF; decrease PETCO2), (b) isocapnic hyperthermia (increased core temperature; no change CBF; no change PETCO2) and (c) isocapnic hyperthermia + indomethacin (increased core temperature; decrease CBF; no change PETCO2). During each manipulation, neuromuscular function will be evaluated and compared to baseline (normothermic) conditions using a repeated measures design.

It is hypothesized that changes in PETCO2 and therefore, changes in cerebral alkalosis will contribute to neuromuscular fatigue independent of changes in CBF or increases in core temperature.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date December 2016
Est. primary completion date June 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- 18 to 45 yrs old; healthy males

Exclusion Criteria:

- diagnosed medical condition; NSAID allergy; smoker; high altitude exposure; implants

Study Design


Intervention

Drug:
Indomethacin

Placebo


Locations

Country Name City State
Canada Brock University St Catharines Ontario

Sponsors (1)

Lead Sponsor Collaborator
Brock University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Resting motor threshold Motor evoked potentials are recorded from muscles following transcranial magnetic stimulation of motor cortex. The resting motor threshold is defined as the minimum stimulation intensity required to elicit a motor evoked potential. Resting motor threshold will be quantified in millivolts. Change from baseline 90-minutes
Primary H-Reflex Amplitude The H-Reflex is an indirect measure of motor neuron excitability. Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed. The peak-to-peak amplitude of this waveform is considered M-max. Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated. The amplitude of the H-reflex will be quantified in millivolts. Change from baseline 90-minutes
Primary Maximal Voluntary Contraction During maximal voluntary contraction (MVC) testing, the participants' right arm will be secured in a custom made device used to isolate forearm flexion and to measure force production by the flexor carpi radialis muscle. Participants will be asked to produce a 5-second MVC and will be verbally encouraged to maintain maximal force production throughout the duration of the contraction. MVC will be quantified as the maximum force production in newton meters. Change from baseline 90-minutes
Primary H-Reflex latency The H-Reflex is an indirect measure of motor neuron excitability. Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed. The peak-to-peak amplitude of this waveform is considered M-max. Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated. The onset latency of the H-reflex will be quantified in milliseconds. Change from baseline 90-minutes
Primary Voluntary Activation The level of neural drive to muscle during contraction is termed voluntary activation and will be estimated by interpolation of a single supramaximal motor evoked potential during the 5-second MVC contraction. If extra force is evoked by the 'superimposed' stimulus then either the stimulated axons were not all recruited voluntarily or they were discharging at sub-tetanic rates. Therefore, voluntary activation will be quantified as the amplitude of maximal voluntary force production, relative to the amplitude of the supramaximal MEP. change from baseline 90-minutes
Secondary Middle Cerebral Artery Blood Flow Velocity Middle cerebral artery (MCA) blood flow velocity will be measured non-invasively by a 2-MHz transcranial Doppler (TCD) ultrasound probe, attached bilaterally to a comfortable headband and secured anterior to the zygomatic arch, rostral of the pinna. Doppler probes will be paced over the temporal windows (near the ear) and will remain in place throughout the duration of the experimental protocol. MCA velocity will be quantified in cm/s. Change from baseline 90-minutes
Secondary Blood Pressure Beat by beat blood pressure will be calculated from the blood pressure waveform using finger photoplethysmography (Nexfin, bmeye), with a finger cuff placed directly over the middle finger on the left hand. Blood pressure will be quantified in mmHg. Change from baseline 90-minutes
Secondary Heart rate Heart rate will be measured by electrocardiogram. Heart rate will be quantified in beats per minute. Change from baseline 90-minutes
Secondary End-tidal Gas concentrations The end-tidal concentrations of oxygen and carbon dioxide will be measured and reported in mmHg. change from baseline 90-minutes
Secondary Rectal Temperature Rectal temperature will be measured in degrees Celsius change from baseline 90-minutes
Secondary Skin Temperature skin temperature will be measured in degrees Celsius change from baseline 90-minutes
See also
  Status Clinical Trial Phase
Recruiting NCT04234594 - Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males. Phase 1
Completed NCT01367561 - Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function Phase 1
Completed NCT00777543 - Increasing Ferulic Acid Bioavailability in Bran N/A
Recruiting NCT04756635 - Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity N/A
Completed NCT02156661 - Oxytocin and Emotion Processing Phase 1
Completed NCT05294198 - Beetroot Extract and Its Influence on Cardiovascular and Autonomic Recovery From the Effort in Healthy Males N/A
Completed NCT00839319 - HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone Phase 1/Phase 2
Completed NCT00842751 - Oral T7 Oral Testosterone in Man Phase 2
Completed NCT01847053 - Bioavailability Study of Cinnamon in Healthy Subjects Phase 1/Phase 2
Completed NCT01215292 - ITT4 Intratesticular Hormonal Milieu in Man (ITT4) Phase 1/Phase 2
Completed NCT00782392 - Bioavailability and Dosing of a Monosaccharide Supplement in Adults N/A
Completed NCT03714685 - Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations Phase 1
Completed NCT05277597 - Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota N/A
Completed NCT01032616 - Uptake and Utilization of Amino Acids by Splanchnic Bed Phase 1
Completed NCT01830335 - Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress Phase 4
Completed NCT00902512 - Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations Phase 4
Completed NCT00475371 - A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males Phase 1
Completed NCT01870102 - Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects Phase 1